INVEGA TRINZA Drug Patent Profile

When do Invega Trinza patents expire, and when can generic versions of Invega Trinza launch?

Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Trinza

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA TRINZA

International Patents:	59
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA TRINZA

Paragraph IV (Patent) Challenges for INVEGA TRINZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24

US Patents and Regulatory Information for INVEGA TRINZA

INVEGA TRINZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-004	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015		RX	Yes	Yes	10,143,693

International Patents for INVEGA TRINZA

When does loss-of-exclusivity occur for INVEGA TRINZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA TRINZA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016244801
Australia	2020239611
Australia	2022221405

Supplementary Protection Certificates for INVEGA TRINZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0904081	SPC/GB11/044	United Kingdom		PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	C300491	Netherlands		PRODUCT NAME: PALIPERIDONPALMITAAT; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304

INVEGA TRINZA (Paliperidone Palmitate Extended-Release Injectable) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

Invega Trinza, a long-acting injectable antipsychotic, presents a stable revenue stream within the schizophrenia and schizoaffective disorder market. Its established efficacy, convenient dosing regimen, and strong patent protection support its current market position. Key drivers for continued investment include an aging population, increasing diagnosis rates, and the drug's proven adherence benefits over oral formulations. However, potential headwinds exist, including generic competition for older paliperidone formulations, the emergence of novel long-acting injectables, and evolving payer reimbursement policies.

Market Landscape and Competitive Positioning

Invega Trinza is a second-generation (atypical) antipsychotic for the treatment of schizophrenia and schizoaffective disorder. It is a long-acting injectable (LAI) formulation of paliperidone palmitate, administered quarterly. This LAI format addresses a critical unmet need in chronic psychiatric care: patient adherence to daily oral medication.

The global antipsychotics market is substantial, projected to reach approximately $22.5 billion by 2028, with LAIs representing a growing segment [1]. Invega Trinza competes directly with other LAI antipsychotics, including Johnson & Johnson's own Invega Sustenna (monthly paliperidone palmitate), Risperdal Consta (risperidone palmitate), Abilify Maintena (aripiprazole lauroxil), and Aristada (aripiprazole lauroxil) [2].

Invega Trinza's primary competitive advantage is its quarterly dosing. This offers a significant improvement in convenience and adherence compared to monthly or less frequent injections, reducing the burden on patients and caregivers. Clinical studies have demonstrated that LAIs, including Invega Trinza, are associated with lower relapse rates and improved patient outcomes compared to oral antipsychotics due to enhanced adherence [3].

Patent Protection and Market Exclusivity

Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, holds significant patent protection for Invega Trinza. The core patent for paliperidone palmitate is set to expire in 2025 in the United States [4]. However, several secondary patents and formulation patents extend exclusivity beyond this date.

• Core Composition of Matter Patents: These patents cover the paliperidone palmitate molecule itself.
• Formulation Patents: These patents protect the specific extended-release technology that enables the quarterly dosing. This is a critical area of protection for Invega Trinza.
• Method of Treatment Patents: Patents may cover specific uses or treatment regimens.

The precise expiration dates of all relevant patents require diligent analysis. While the primary composition of matter patent is approaching expiration, the strength and duration of the formulation and method of treatment patents are crucial for forecasting Invega Trinza's market exclusivity. Early generic entry for paliperidone palmitate may be limited by the complexity of replicating the extended-release formulation and achieving bioequivalence for quarterly administration. However, patent litigation is a common feature in the pharmaceutical industry, and potential challenges from generic manufacturers should be monitored.

Financial Performance and Market Share

Invega Trinza has been a significant contributor to Johnson & Johnson's pharmaceutical segment.

• Sales Data: Invega Trinza generated approximately \$2.2 billion in sales in 2022 [5]. This represents a slight increase from \$2.1 billion in 2021.
• Growth Trends: The drug has demonstrated consistent, albeit moderate, year-over-year sales growth, reflecting its established market presence and the continued demand for effective LAI treatments.
• Market Share: Invega Trinza holds a substantial share within the LAI antipsychotics market, benefiting from its superior dosing frequency compared to competitors like Risperdal Consta and Abilify Maintena. Its closest competitor in terms of LAI advantage is often Invega Sustenna, the monthly formulation, with which it shares the same active pharmaceutical ingredient.

The financial trajectory of Invega Trinza is influenced by several factors:

• Reimbursement: Favorable reimbursement from major payers (e.g., Medicare, Medicaid, private insurers) is essential for market access and sales volume.
• Physician Adoption: Prescribing patterns by psychiatrists and mental health professionals are critical.
• Generic Competition: As patents expire, the threat of generic versions looms, which can significantly erode market share and pricing power.

R&D Pipeline and Future Prospects

Johnson & Johnson's R&D strategy concerning paliperidone palmitate has historically focused on optimizing delivery and patient convenience. The development of Invega Trinza from Invega Sustenna exemplifies this.

• Pipeline Status: There are no major pipeline advancements directly related to Invega Trinza itself. The focus has shifted to maintaining its market position and exploring broader applications for the paliperidone palmitate franchise.
• Life Cycle Management: Life cycle management strategies for Invega Trinza will likely involve:
  • Post-marketing studies: Demonstrating long-term efficacy and safety.
  • Health economics and outcomes research (HEOR): Reinforcing the value proposition of LAIs in reducing healthcare utilization and costs.
  • Geographic expansion: Pursuing approvals in emerging markets.
• Therapeutic Area Expansion: While Invega Trinza is approved for schizophrenia and schizoaffective disorder, further exploration of its utility in other psychiatric conditions, if supported by clinical data and regulatory pathways, could represent future growth. However, current clinical evidence primarily supports its use in the approved indications.

Risk Factors and Mitigation Strategies

Investing in Invega Trinza carries specific risks that require careful consideration.

• Patent Expiration and Generic Entry:
  • Risk: The expiration of the core patent in 2025 opens the door for generic manufacturers to launch bioequivalent versions. This can lead to significant price erosion and loss of market share.
  • Mitigation: Johnson & Johnson's defense strategy will likely rely on the strength of its secondary formulation patents and potential litigation to delay or prevent generic entry. The complexity of developing and manufacturing a stable quarterly LAI formulation may also serve as a barrier to entry for some generic companies.
• Emergence of Novel LAI Therapies:
  • Risk: Pharmaceutical companies are actively developing new LAI antipsychotics with potentially improved efficacy, safety profiles, or novel mechanisms of action. These could challenge Invega Trinza's market dominance.
  • Mitigation: Continued investment in post-marketing studies to reinforce Invega Trinza's proven track record and focusing on its unique quarterly dosing advantage will be crucial.
• Payer Reimbursement Pressures:
  • Risk: Healthcare payers are increasingly scrutinizing drug costs and may implement stricter reimbursement policies, formulary restrictions, or prior authorization requirements for expensive LAI medications.
  • Mitigation: Demonstrating the cost-effectiveness of Invega Trinza through HEOR data, highlighting its role in preventing costly relapses and hospitalizations, is essential. Building strong relationships with payers and advocating for LAI coverage are ongoing strategies.
• Competition from Other Paliperidone Formulations:
  • Risk: Invega Sustenna (monthly) and oral paliperidone, also marketed by Janssen, compete for market share within the paliperidone franchise. Prescriber preference and patient choice can influence the adoption of one formulation over another.
  • Mitigation: Differentiating the benefits of quarterly administration (Invega Trinza) versus monthly (Invega Sustenna) or daily oral administration is key. Educational initiatives targeting healthcare providers and patients about the advantages of longer-acting formulations can support Invega Trinza's positioning.
• Adverse Event Profile and Safety Concerns:
  • Risk: Like all antipsychotics, Invega Trinza has an established adverse event profile that may limit its use in certain patient populations or lead to prescribing caution.
  • Mitigation: Robust pharmacovigilance programs and transparent communication of safety information are standard industry practices. Clinical data reinforcing a favorable risk-benefit profile for its approved indications are critical.

Key Takeaways

Invega Trinza (paliperidone palmitate extended-release injectable) represents a mature, yet resilient, pharmaceutical asset. Its quarterly dosing is a significant differentiator in the long-acting injectable antipsychotic market, contributing to strong adherence and patient outcomes in schizophrenia and schizoaffective disorder. The drug's financial performance has been robust, underpinned by consistent sales and favorable market positioning.

However, the upcoming expiration of core patent protection in 2025 presents a material risk of generic competition. While formulation patents may offer some delay, this event necessitates a proactive investment strategy that accounts for potential market share erosion and pricing pressures. The competitive landscape is dynamic, with ongoing innovation in LAI therapies and evolving payer dynamics requiring continuous adaptation. For investors, a detailed analysis of the remaining patent life for formulation and method-of-treatment patents, alongside an assessment of Johnson & Johnson's litigation and market defense strategies, is paramount.

Frequently Asked Questions

1. What is the primary mechanism of action for Invega Trinza? Invega Trinza is an atypical antipsychotic that acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist [6]. Paliperidone, the active metabolite of risperidone, modulates these neurotransmitter systems to help manage symptoms of schizophrenia and schizoaffective disorder.

2. What are the key advantages of Invega Trinza over oral antipsychotics? The primary advantage of Invega Trinza is its long-acting injectable formulation, administered quarterly. This significantly improves medication adherence compared to daily oral medications, which is a common challenge in managing chronic psychiatric conditions. Improved adherence is often associated with reduced relapse rates and better overall patient outcomes [3].

3. When is the primary patent for Invega Trinza set to expire, and what are the implications? The core patent for paliperidone palmitate is scheduled to expire in 2025 in the United States [4]. Upon patent expiration, generic manufacturers are typically able to introduce their own versions of the drug. This can lead to significant price reductions and a potential loss of market share for the innovator product.

4. Beyond patent expiration, what are the other significant competitive threats to Invega Trinza? Other competitive threats include the development and market introduction of novel long-acting injectable antipsychotics that may offer improved efficacy, safety profiles, or more convenient dosing schedules. Additionally, the presence of other paliperidone formulations, such as the monthly Invega Sustenna, and the general market penetration of other LAI drugs like aripiprazole lauroxil and risperidone palmitate, represent ongoing competitive pressures.

5. How does Johnson & Johnson typically defend its products against generic competition for long-acting injectables? For long-acting injectables, defending against generic competition often involves a multi-pronged strategy. This includes leveraging secondary patents related to specific formulations, delivery mechanisms, and methods of use, which may extend market exclusivity beyond the primary composition of matter patent. Johnson & Johnson also engages in patent litigation to challenge generic entrants and employs strategies to educate healthcare providers and patients on the clinical benefits and value proposition of their branded product, emphasizing its established efficacy and safety record.

Citations

[1] Global Market Insights. (2023). Antipsychotics Market Size, Share & Industry Analysis. Global Market Insights Report. [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm [3] Tiihonen, T., Suokas, V., & Lehtiniemi, H. (2016). Long-acting injectable antipsychotics in the treatment of schizophrenia. Psychopharmacology, 233(12), 2305–2315. [4] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/ [5] Johnson & Johnson. (2023). Form 10-K Annual Report for the fiscal year ended December 31, 2022. Retrieved from https://www.sec.gov/edgar/searches/companysearch [6] U.S. National Library of Medicine. (n.d.). Paliperidone Palmitate Extended-Release Injectable. Drug Information Portal. Retrieved from https://pubchem.ncbi.nlm.nih.gov/